CD8A and myeloid sarcoma: Finally, we observed that absolute numbers of CSF CD8+ T cells and B cells as well as the B cell/monocyte ratio showed a statistically significant negative correlation with length of treatment, suggesting that the efficacy of daclizumab on these markers of CSF inflammation associated with MS increased with the length of therapy.